Showing 1811-1820 of 2192 results for "".
- Study Compares Nurtec ODT vs 14 Other Treatments for Acute Migrainehttps://practicalneurology.com/news/study-compares-nurtec-odt-vs-14-other-treatments-for-acute-migraine/2475275/Nurtec ODT (rimegepant; Pfizer, New York, NY) treatment for acute migraine was found to have superior or comparable efficacy and a more favorable safety profile compared with 14 other commonly used medications, which included triptans, nonsteroidal anti-inflammatory drugs (NSAIDs), and compound a
- Vagus Nerve Stimulation Paired With Rehabilitation Yields Sustained Upper Limb Recovery in Individuals With Strokehttps://practicalneurology.com/news/vagus-nerve-stimulation-paired-with-rehabilitation-yields-sustained-upper-limb-recovery-in-individuals-with-stroke/2474624/According to post hoc analysis of the VNS-REHAB clinical trial (NCT03131960), vagus nerve stimulation (VNS) paired with upper extremity (UE) rehabilitation showed significant improvements in UE impairment, activity, and quality-of-life (QoL) measures in individuals who experienced ischemic stroke
- Carotid Revascularization Superior to Medical Management in Preventing Recurrent Stroke in People with Ipsilateral Carotid Webhttps://practicalneurology.com/news/carotid-revascularization-superior-to-medical-management-in-preventing-recurrent-stroke-in-people-with-ipsilateral-carotid-web/2473950/Relative to carotid revascularization, medical management (antiplatelet or anticoagulation therapy) was associated with increased risk of recurrent ischemic stroke in patients with ischemic stroke and ipsilateral carotid web according to results of a systematic review and meta-analysis presented
- Long-Term Seizure Reduction Seen with 5-HT2C Receptor Superagonist Treatment in Those with DEEshttps://practicalneurology.com/news/treatment-with-bexicaserin-associated-with-seizure-frequency-reduction-for-people-with-developmental-and-epileptic-encephalopathies/2473786/Treatment of seizures using bexicaserin (Lundbeck, Deerfield, IL) was associated with improved long-term efficacy, safety, and tolerability outcomes for individuals with developmental and epileptic encephalopathies (DEEs) in the results of a 12-month open-label extension (OLE) study. Individuals
- The FDA Approved a New Oral, As-Needed Tablet for Acute Migraine Treatmenthttps://practicalneurology.com/news/the-fda-approved-a-new-oral-as-needed-tablet-for-acute-migraine-treatment/2473775/The Food and Drug Administration (FDA) has approved Symbravo (meloxicam and rizatriptan; Axsome Therapeutics, New York, NY) for the acute treatment of adults diagnosed with migraine with or without aura. Symbravo, previously known as AXS-07, is a single-dose, oral medication for use as-needed. Ax
- Promising Results for mAb Migraine Treatment Targeting PACAP Reported in NEJMhttps://practicalneurology.com/news/promising-results-for-mab-migraine-treatment-targeting-pacap-reported-in-nejm/2470582/A single intravenous infusion of Lu AG09222 (Lundbeck, Deerfield, IL), a humanized monoclonal antibody (mAb) that targets the pituitary adenylate cyclase-activating polypeptide (PACAP) ligand, was found to be superior to placebo in reducing migraine frequency over 4 weeks. The results of a phase
- Stem Cell Therapy Superior to Lemtrada for Treating RRMS According to Real-World Datahttps://practicalneurology.com/news/stem-cell-therapy-superior-to-lemtrada-for-treating-rrms-according-to-real-world-data/2470578/According to an analysis of data from a real-world setting, people with relapsing-remitting multiple sclerosis (RRMS) treated with autologous hematopoietic stem cell transplantation (AHSCT) showed improved clinical and radiologic outcomes compared with those treated with Lemtrada (alemtuzumab; Sa
- Uplizna Treatment for NMOSD Shows Sustained Clinical Benefit Over 4 Years According to Full N-MOmentum Datahttps://practicalneurology.com/news/uplizna-treatment-for-nmosd-shows-sustained-clinical-benefit-over-4-years-according-to-full-n-momentum-data/2470476/New end-of-study results from the N-MOmentum clinical trial (NCT02200770) which included data from the randomized controlled period and the open-label extension periods were published in The Lancet Neurology. According to the findings, long-term treatment with Uplizna (inebilizumab-cdon;
- One-Year Data from OCARINA II Show Suppression of Relapses/Lesions in MS with Subcutaneous Ocrevus Treatmenthttps://practicalneurology.com/news/one-year-data-from-ocarina-ii-show-suppression-of-relapseslesions-in-ms-with-subcutaneous-ocrevus-treatment/2470456/Data from the OCARINA II study (NCT05232825) presented at the American Academy of Neurology (AAN) 2024 Annual Meeting showed that subcutaneous (SC) injection of Ocrevus (ocrelizumab; Genentech, South San Francisco, CA) resulted in near-complete suppression of clinical relapses and brain lesions i
- Protein Levels in Plasma Highly Predictive of Future Dementia Risk According to UK Biobank Studyhttps://practicalneurology.com/news/protein-levels-in-plasma-highly-predictive-of-future-dementia-risk-according-to-uk-biobank-study/2470405/People with higher baseline plasma levels of certain proteins, including glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), growth/differentiation factor 15 (GDF15), and latent-transforming growth factor beta-binding protein 2 (LTBP2), had an elevated risk of developing deme